Credit Industriel ET Commercial Boosts Stock Position in LENSAR, Inc. $LNSR

Credit Industriel ET Commercial increased its position in LENSAR, Inc. (NASDAQ:LNSR) by 98.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 168,600 shares of the company’s stock after acquiring an additional 83,600 shares during the quarter. Credit Industriel ET Commercial owned about 1.43% of LENSAR worth $2,220,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in LNSR. Gabelli Funds LLC bought a new position in shares of LENSAR in the first quarter worth approximately $191,000. PenderFund Capital Management Ltd. purchased a new position in shares of LENSAR during the 1st quarter valued at $236,000. Nuveen LLC purchased a new position in shares of LENSAR during the 1st quarter valued at $252,000. Acadian Asset Management LLC bought a new position in LENSAR in the 1st quarter worth $257,000. Finally, Cubist Systematic Strategies LLC bought a new position in LENSAR in the 1st quarter worth $369,000. Hedge funds and other institutional investors own 40.15% of the company’s stock.

LENSAR Stock Performance

Shares of NASDAQ:LNSR opened at $10.60 on Friday. The firm has a market cap of $126.56 million, a price-to-earnings ratio of -2.41 and a beta of 0.49. The firm has a fifty day moving average price of $12.14 and a 200 day moving average price of $12.81. LENSAR, Inc. has a fifty-two week low of $6.52 and a fifty-two week high of $17.31.

LENSAR (NASDAQ:LNSR) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.23). The company had revenue of $14.32 million during the quarter, compared to the consensus estimate of $17.75 million. LENSAR had a negative net margin of 87.12% and a negative return on equity of 737.30%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of LENSAR in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $15.00.

About LENSAR

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.